Utility of disease modifying antirheumatic drugs in 'sawtooth' strategy. A prospective study of early rheumatoid arthritis patients up to 15 years

Annals of the Rheumatic Diseases

Volumn 58, Issue 10, 1999, Pages 618-622

  Sokka, T ^a   Hannonen, P ^a  

^a JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; AURANOFIN; AZATHIOPRINE; CHLORAMBUCIL; CPH 82; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HYDROXYCHLOROQUINE; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE; TENIDAP;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LONG TERM CARE; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; REMISSION; RHEUMATOID ARTHRITIS; SKIN TOXICITY; TREATMENT OUTCOME;

EID: 0032833160     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.58.10.618     Document Type: Article

References (25)

1. Wilske KR, Healey LA. Remodeling the pyramid-a concept whose time has come. J Rheumatol 1989;16:565-7.
2. Fries JF. Reevaluating the therapeutic approach to rheumatod arthritis: the 'sawtooth' strategy. J Rheumatol 1990;17:12-15.
3. Pincus T, Callahan LF. Remodeling the pyramid or remodeling the paradigms concerning rheumatoid arthritis-lessons from Hodgin's disease and coronary artery disease. J Rheumatol 1990;17:1582-5.
4. Hess EV, Luggen ME. Remodeling the pyramid-a concept whose time has not yet come. J Rheumatol 1989;16:1175-6.
5. Möttönen TT. Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthtitis. Ann Rheum Dis 1988;47;648-53.
6. Hannonen P, Möttönen T, Hakola M, Oka M. Sulphasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 1993;36:1501-9.
7. Ropes MW, Bennet GA, Cobb S, Jacox RA, Jessar R. 1958 revision of diagnostic criteria for rheumatoid arthritis. Arthritis Rheum 1959;2:16-20.
8. Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24:1308-15.
9. Situnayake RD, Grindulis KA, McConkey B. Long term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods. Ann Rheum Dis 1987;46:177-83.
10. Thompson RW, Kirwan JR, Barnes CG. Practical results of treatment with disease-modifying antirheumatoid drugs. Br J Rheumatol 1985;24:167-75.
11. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II Second line drugs and prednisone. J Rheumatol 1992;19:1885-94.
12. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: A 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990; 17:994-1002.
13. De La Mata J, Blanco FJ, Gomez-Reino JJ. Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients. Ann Rheum Dis 1995;54:881-5.
14. Wijnands MJH, van't Hof MA, van Leeuwen MA, van Rijswijk MH, van de Putt LBA, van Riel PLCM. Long-term second-line treatment: a prospective drug survival study. Br J Rheumatol 1992;31:253-8.
15. Jessop JD, O'Sullivan MM, Lewis PA, Williams LA, Camilleri JP, Plant MJ, et al. A long-term five-year randomized controlled trial of hydroxychloroquine, sodium aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritis. Br J Rheumatol 1998;37:992-1002.
16. Pincus T, Wolfe F, Stein CM. 'No evidence of disease' in rheumatoid arthritis using methotrexate in combination with other drugs: A contemporary goal for rheumatology care? Clin Exp Rheumatol 1997;15:591-6.
17. Sokka T, Kautiainen H, Hannonen P. A retrospective study of treating RA patients with various combinations of slow-acting antirheumatic drugs in a county hospital. Scand J Rheumatol 1997;26:440-3.
18. Bologna C, Viu F, Picot MC, Jorgensen C, SanyJ. Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study. Br J Rheumatol 1997;16:535-40.
19. Van Gestel AM, Haagsma CJ, Furst DE, van Riel PLCM. Treatment of early rheumatoid arthritis patients with slow-acting anti-rheumatic drugs (SAARDs). Bailliers Clin Rheumatol 1997;11:65-82.
20. Wolfe F, Hawley DJ. Remission in rheumatoid arthritis. J Rheumatol 1985;12:245-52.
21. Suarez-Almazor ME, Soskolne CL, Saunders LD, Russell AS. Use of second line drugs for the treatment of rheumatoid arthritis in Edmonton, Alberta. Patterns of prescription and longterm effectiveness. J Rheumatol 1995;22:836-43.
22. O'Dell JR, Haire CE, Palmer W, Drymalski W, Wees S, Blakely K, et al. Treatment of early rheumatoid arthritis with minocycline or placebo. Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1997,40:842-8.
23. Eberhardt KB, Rydgren LC, Pettersson H, Wollheim FA. Early rheumatoid arthritis: onset, course, and outcome over 2 years. Rheumatol Int 1990;10:135-42.
24. Boers M, Verhoeven AC, Markusse HM, van de Laar MAFJ, Westhovens R, van Denderen JC, et al. Randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
25. Möttönen T, Hannonen P, Leirisalo-Repo M, Nissilä M, Kautiainen H, Korpelath M, et al. Randomized trial of combination therapy with sulphasalazine, methotrexate, hydroxychloroquine and prednisolone with sigle drug therapy in patients with early rheumatoid arthritis. Lancet 1999;353:1568-73.